VistaGen Therapeutics, Inc.
VTGN
$1.97
-$0.08-3.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -54.28% | -33.01% | 7.96% | 369.44% | 568.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -54.28% | -33.01% | 7.96% | 369.44% | 568.49% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -54.28% | -33.01% | 7.96% | 369.44% | 568.49% |
| SG&A Expenses | 21.48% | 30.03% | 34.68% | 21.80% | -4.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.65% | 53.21% | 27.00% | -15.19% | -42.27% |
| Operating Income | -69.51% | -55.86% | -27.44% | 17.94% | 44.29% |
| Income Before Tax | -75.12% | -47.50% | -11.50% | 28.42% | 50.44% |
| Income Tax Expenses | 75.00% | 128.57% | 128.57% | -71.43% | -33.33% |
| Earnings from Continuing Operations | -75.12% | -47.51% | -11.52% | 28.43% | 50.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.12% | -47.51% | -11.52% | 28.43% | 50.44% |
| EBIT | -69.51% | -55.86% | -27.44% | 17.94% | 44.29% |
| EBITDA | -69.71% | -56.02% | -27.51% | 17.98% | 44.38% |
| EPS Basic | 21.67% | 56.13% | 72.42% | 76.75% | 75.09% |
| Normalized Basic EPS | 21.65% | 56.13% | 72.43% | 76.75% | 75.10% |
| EPS Diluted | 21.67% | 56.13% | 72.42% | 76.75% | 75.09% |
| Normalized Diluted EPS | 21.65% | 56.13% | 72.43% | 76.75% | 75.10% |
| Average Basic Shares Outstanding | 59.80% | 127.10% | 285.39% | 255.50% | 177.66% |
| Average Diluted Shares Outstanding | 59.80% | 127.10% | 285.39% | 255.50% | 177.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |